中外医学研究
中外醫學研究
중외의학연구
CHINESE AND FOREIGN MEDICAL RESEARCH
2015年
6期
1-3
,共3页
宫颈癌%同步放化疗%紫杉醇脂质体%奈达铂
宮頸癌%同步放化療%紫杉醇脂質體%奈達鉑
궁경암%동보방화료%자삼순지질체%내체박
Cervical cancer%Concurrent radiochemotherapy%Paclitaxel Liposome%Nedaplatin
目的：研究紫杉醇脂质体联合奈达铂同步放化疗治疗宫颈癌的临床疗效。方法：60例患者随机分为试验组和对照组，各30例，所有患者均接受相同剂量的放疗，试验组同时予紫杉醇脂质体联合奈达铂化疗，治疗结束后对两组患者的临床疗效及不良反应进行统计学分析。结果：试验组总有效率为93.3％，对照组总有效率为66.7％，差异有统计学意义(P<0.05)。试验组的3年生存率(0S)高于对照组(P<0.05)。试验组远处转移率明显低于对照组，差异有统计学意义(P<0.05)。试验组患者骨髓抑制和恶心呕吐不良反应明显高于对照组，差异有统计学意义(P<0.05)，但患者经对症处理后可耐受治疗。结论：紫杉醇脂质体联合奈达铂方案在中晚期宫颈癌同步放化疗中近期疗效明确，减少远处转移的风险，延长患者生存期，不良反应可耐受，值得临床进一步应用。
目的：研究紫杉醇脂質體聯閤奈達鉑同步放化療治療宮頸癌的臨床療效。方法：60例患者隨機分為試驗組和對照組，各30例，所有患者均接受相同劑量的放療，試驗組同時予紫杉醇脂質體聯閤奈達鉑化療，治療結束後對兩組患者的臨床療效及不良反應進行統計學分析。結果：試驗組總有效率為93.3％，對照組總有效率為66.7％，差異有統計學意義(P<0.05)。試驗組的3年生存率(0S)高于對照組(P<0.05)。試驗組遠處轉移率明顯低于對照組，差異有統計學意義(P<0.05)。試驗組患者骨髓抑製和噁心嘔吐不良反應明顯高于對照組，差異有統計學意義(P<0.05)，但患者經對癥處理後可耐受治療。結論：紫杉醇脂質體聯閤奈達鉑方案在中晚期宮頸癌同步放化療中近期療效明確，減少遠處轉移的風險，延長患者生存期，不良反應可耐受，值得臨床進一步應用。
목적：연구자삼순지질체연합내체박동보방화료치료궁경암적림상료효。방법：60례환자수궤분위시험조화대조조，각30례，소유환자균접수상동제량적방료，시험조동시여자삼순지질체연합내체박화료，치료결속후대량조환자적림상료효급불량반응진행통계학분석。결과：시험조총유효솔위93.3％，대조조총유효솔위66.7％，차이유통계학의의(P<0.05)。시험조적3년생존솔(0S)고우대조조(P<0.05)。시험조원처전이솔명현저우대조조，차이유통계학의의(P<0.05)。시험조환자골수억제화악심구토불량반응명현고우대조조，차이유통계학의의(P<0.05)，단환자경대증처리후가내수치료。결론：자삼순지질체연합내체박방안재중만기궁경암동보방화료중근기료효명학，감소원처전이적풍험，연장환자생존기，불량반응가내수，치득림상진일보응용。
Objective:To explore the clinical effect of Paclitaxel Liposome and Nedaplatin in advanced cervical cancer concurrent by radiochemotherapy.Method:60 patients were randomly divided into the experimental group(radiochemotherapy) and the control group(radiotherapy), each group had 30 cases.All of patients were accepted the conventional radiatherapy,the patients of the experimental group were accepted concurrent radiochemotherapy.The clinica1 efficacy and adverse reactions in both groups were analyzed after treatment.Result:The experimental group overall response rate(CR+PR) was 93.3%,it was better than 66.7%of the control group(P<0.05),and the over survival rate of 3 years were higher than the control group(P<0.05).The adverse reactions such as nausea and vomiting and bone marrow suppression in the experimental group patients were significantly higher than the control group patients(P<0.05).But after symptomatic treatment these patients all could complete the treatment plan.Conclusion:The result was shown that Paclitaxel Liposome and Nedaplatin concurrent by radiochemotherapy has clear short-term curative effect in advanced cervical cancer.That can reduce the risk of distant metastases,extend the patients survival,adverse reactions can be tolerated,which is worth further clinical application.
